Agilent Technologies, an analytical and clinical laboratory technologies firm, agreed to acquire BIOVECTRA, a global biotech and pharmaceutical company, for $925m. “BIOVECTRA is excited to join Agilent, a company whose dedication to people and customers is very much aligned with ours. BIOVECTRA has dedicated nearly 55 years to the relentless pursuit of helping our customers solve complex problems that improve patients’ lives. This synergistic pairing of our capabilities with Agilent’s will further enhance the value we can offer to our customers,” Oliver Technow, BIOVECTRA CEO.